drugset / Trial / NCT04126070
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are: * Androgen deprivation therapy (ADT) with a drug of your physician's choice. This may include leuprolide (Lupron), goserelin acetate (Zoladex), or degarelix (Firmagon). * Docetaxel * Nivolumab
Timeline
- Start
- 2020-05-11
- Primary completion
- 2025-07-29
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Background | Degarelix | Other / unclassified | — | Subcutaneous |
| Background | Goserelin | Other / unclassified | — | Subcutaneous |
| Background | Leuprolide | Other / unclassified | — | Intramuscular |